Outlook Therapeutics Seeks Permanent J-Code for LYTENAVA to Streamline U.S. Reimbursement

  • Outlook Therapeutics submitted an HCPCS Level II application to CMS for a permanent J-code for LYTENAVA (bevacizumab-vikg).
  • The company aims to secure a clear reimbursement pathway ahead of its planned U.S. commercial launch before year-end 2026.
  • LYTENAVA is the only FDA-approved ophthalmic bevacizumab for treating wet age-related macular degeneration (wet AMD).
  • A permanent J-code would streamline billing, reduce administrative burden, and support broader practice adoption.

Outlook Therapeutics' submission for a permanent J-code is a strategic move to ensure smooth reimbursement and broad market access for LYTENAVA in the U.S. This step is crucial as the company prepares for its commercial launch before year-end 2026. The approval of a J-code would facilitate billing and reimbursement, potentially accelerating adoption among retina practices. The company's focus on market access and reimbursement readiness underscores the competitive landscape in the treatment of wet AMD, where efficient reimbursement pathways can significantly impact market penetration.

Regulatory Approval
Whether CMS will assign a permanent J-code for LYTENAVA, which is critical for reimbursement and market access.
Market Adoption
The pace at which U.S. retina practices adopt LYTENAVA following its commercial launch.
Revenue Potential
How successful Outlook Therapeutics will be in generating revenue from LYTENAVA in the U.S. and European markets.